Page 7 - emap_newsletter_V2

eMAP – electronic EHA Medical HemAtology Program

Patient Characteristics =12mo <12mo P Patients with poorer survival (<12 months) were associated with
26 109 a higher proportion being ineligible for ZUMA1, being less likely
Survival 56 (20-79) 57 (21-83) n.s. to be bridging responders, and having had an early relapse
n 15 (71%) 73 (65%) n.s. (within 30 days of CAR T). Those with better survival (=12
Median age 11 (42%) 62 (57%) n.s. months) had a higher proportion of bridging responders, were
Male 12 (46%) 68 (62%) n.s. more likely to have a later relapse (after 100 days post-CAR
IPI high/high-intermediate @ LD 19 (73%) 104 (95%) 0.0019 T), and were more likely to receive allogeneic HSCT. Note that
LDH >Normal @ LD 15 (58%) 28 (27%) 0.0047 of the 40 patients who proceeded to allogeneic HSCT post-
ZUMA1 ineligible relapse/progression, the 12-month OS was 34%.
Bridging responders / no 1/24 (4%) 17/103 (17%) n.s.
bridging 24 (92%) 76 (70%) 0.023 The study authors concluded that long-term survival after failure
ECOG =2 @ LD 7 (27%) 34 (31%) n.s. of CAR T therapy is possible in about 20% of patients with
=3 Treatment lines 15 (58%) 71 (65%) n.s LBCL, with predictors of favourable survival including good-
Prior SCT 1 (4%) 26 (24%) 0.027 risk pre-CAR T features and a long interval between CAR T
Tisa-cel 12 (46%) 22 (20%) 0.011 therapy and relapse. Of important note, allogenic HSCT for
REL after CAR-T =30d 13 (50%) 26 (24%) 0.015 consolidation of treatment responses post-relapse/progression
REL after CAR-T >100d 9 (35%) 30 (28%) n.s. may improve outcomes of CAR T failure.
alloHSCT performed 4 (15%) 8 (7%) n.s.
1st salvage Pola-based 1 (4%) 7 (6%) n.s.
1st salvage CPi-based
1st salvage Lena-based

CAR, chimeric antigen receptor; CPi, checkpoint inhibitor; ECOG, Eastern Cooperative Oncology Group;
HSCT, hematopoietic stem cell transplantation; IPI, International Prognostic Index score; LD, limited
disease; LDH, lactate dehydrogenase; Lena, lenalidomide; Pola, polatuzumab vedotin; REL, relapse/
progression; SCT, stem cell transplant.

WATCH WATCH
DR. KURUVILLA’S IN-DEPTH PRESENTATION OF THIS DR. KURUVILLA’S THOUGHTS ON THE RELEVANCE OF
ABSTRACT (~4 MINUTES) THESE DATA TO CANADIAN PRACTICE (~2 MINUTES)

CLICK HERE FOR THE LINK TO THE FULL ABSTRACT

TABLE OF CONTENTS 7